Vivesto AB
STO:VIVE

Watchlist Manager
Vivesto AB Logo
Vivesto AB
STO:VIVE
Watchlist
Price: 0.1392 SEK 2.96% Market Closed
Market Cap: 74.9m SEK

Profitability Summary

Vivesto AB's profitability score is 22/100. We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

22/100
Profitability
Score

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

22/100
Profitability
Score
22/100
Profitability
Score

Past Growth

Analyzing past growth in Revenue, Operating Income, and Net Income allows investors to assess the company's profitability and operational efficiency. Consistent improvement in these metrics typically signals long-term strength and stability.

Show More Less

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Show More Less

Earnings Waterfall
Vivesto AB

Revenue
0 SEK
Operating Expenses
-36.4m SEK
Operating Income
-36.4m SEK
Other Expenses
702k SEK
Net Income
-35.7m SEK

Margins Comparison
Vivesto AB Competitors

Country Company Market Cap Operating
Margin
Net
Margin
SE
Vivesto AB
STO:VIVE
74.9m SEK N/A N/A
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
-21 040%
US
Abbvie Inc
NYSE:ABBV
405.2B USD
33%
4%
US
Amgen Inc
NASDAQ:AMGN
178.2B USD
34%
19%
US
Gilead Sciences Inc
NASDAQ:GILD
154.5B USD
39%
28%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
117.3B USD
39%
31%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
-392%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.3B USD
28%
32%
AU
CSL Ltd
ASX:CSL
83B AUD
26%
19%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.7B USD
8%
1%
NL
argenx SE
XBRU:ARGX
44B EUR
22%
43%
No Stocks Found

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Show More Less

Return on Capital Comparison
Vivesto AB Competitors

Country Company Market Cap ROE ROA ROCE ROIC
SE
Vivesto AB
STO:VIVE
74.9m SEK
-24%
-21%
-24%
-25%
FR
Pharnext SCA
OTC:PNEXF
6T USD
115%
-391%
275%
3 093%
US
Abbvie Inc
NYSE:ABBV
405.2B USD
139%
2%
20%
28%
US
Amgen Inc
NASDAQ:AMGN
178.2B USD
82%
8%
17%
15%
US
Gilead Sciences Inc
NASDAQ:GILD
154.5B USD
41%
14%
25%
19%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
117.3B USD
22%
16%
23%
25%
US
Epizyme Inc
F:EPE
94.1B EUR
-877%
-67%
-73%
-182%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.3B USD
15%
12%
11%
12%
AU
CSL Ltd
ASX:CSL
83B AUD
16%
8%
12%
10%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.7B USD
33%
1%
8%
-21%
NL
argenx SE
XBRU:ARGX
44B EUR
30%
26%
15%
62%
No Stocks Found

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

Show More Less